JAMA Oncology

EMBARGOED FOR RELEASE: 5:30 P.M. (ET), SUNDAY, JUNE 1, 2025

Media advisory: The full study and editor’s note are linked to this news release. This study is being presented at the 2025 American Society of Clinical Oncology Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2025.1002?guestAccessKey=1631ff64-3f47-4d6e-b4bd-d757aea0d7f5&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060125

About The Study: Although phase 3 trials are often interpreted as demonstrating superiority, overall survival and quality of life (QOL), which may be the most relevant end points to patients, are uncommonly improved. To increase the meaningfulness of late-phase research, future trial designs and regulatory processes should be refocused toward overall survival and QOL improvements.

Corresponding Author: To contact the corresponding author, Alexander D. Sherry, MD, email alexanderdsherry@gmail.com.

(doi:10.1001/jamaoncol.2025.1002)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.